AzTrials
AzTrials

GERDFeedGERDNCT03031288

Effects of Vented Base Feeding Bottle in Preterm Infants With GERD Symptoms.

A study testing A and B in people with GERD and Apnea Neonatal, run by University of Turin, Italy at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Aim of the study is to evaluate the effects of vented base bottles on respiration-swallow patterns and on gastroesophageal refluxes in preterm infants with clinical suspect of gastroesophageal reflux disease (GERD). Read more about this study

Who is it for?
Ages 1 week to 3 months
Conditions the study is for
GERD, Apnea Neonatal
What is being tested?
A and B
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteItaly
Study dates
1 Jan 2017to 1 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 week to 3 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • weight ≥ 1500 g at the time of examination
  • at least 2 GERD symptoms
  • exclusive enteral feeding
  • parents' informed consent

Who cannot join

  • congenital abnormalities
  • perinatal asphyxia
  • respiratory, genetic, metabolic, infectious and/or neurologic disease
  • pharmacological therapies, in the last 7 days, able to affect esophageal motility

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Ospedale S.Anna di Torino

    Torino, (TO), 10126

Other trials in Italy

About this study

Official title: Vented Base Feeding Bottle in Preterm Infants With GERD Symptoms: Effects on Respiration-swallow Patterns and Reflux.

Aim of the study is to evaluate the effects of vented base bottles on respiration-swallow patterns and on gastroesophageal refluxes in preterm infants with clinical suspect of gastroesophageal reflux disease (GERD).

In this crossover-randomized study, we compared the effects of standard feeding bottles (A) versus vented base feeding bottles (B) on a group of patients with at least 2 clinical GERD symptoms. 24 hours of synchronized cardiorespiratory (CR) and Esophageal Multichannel intraluminal impedance (MII/pH) monitoring were evaluated for each patient. During this period, patients were fed alternatively with feeding bottle A and B.

Read the detailed description

In preterm infants a deficit of both coordination and gastro-intestinal motility is often the underpinning cause of oxygen desaturations and gastro-esophageal reflux. Breastfeeding enhances the maturation of the respiration-swallow mechanism. For this reason, a feeding bottle that best recreates the physiological sucking from the maternal breast is highly desirable in non-breastfed newborns.

Population: newborns referred to esophageal Multichannel Intraluminal Impedance and pH-metry (MII/pH) combined with cardiorespiratory (CR) monitoring for GERD or cardio-respiratory symptoms

Materials and methods: we compare the effects of traditional feeding bottles (A) versus vented base feeding bottles (B) on cardiorespiratory and reflux events in newborns undergoing 24 hours synchronized CR and MII/pH monitoring. During the exam, newborns are fed, alternatively, by feeding bottle A and B with human milk or formula. Some training meals are offered the day before monitoring to get newborns enrolled into the study used to vented base feeding bottles.

Cardiorespiratory monitoring is performed through VitaGuard VG3100® (Getemed Medizin- und Informationstechnik AG, Teltow, Germany) based on Masimo Signal Extraction Technology (SET)® (Masimo Corp., Irvine, CA, USA). It operates with a blood oxygen saturation (SpO2) detector, placed on the right wrist, and 3 thoracic electrodes. This instrument is able to record ECG, heart rate, SpO2 and thoracic plethysmographic curve. The signals are analyzed with VitaWin 3® software (Getemed Medizin - und Informationstechnik AG, Teltow, Germany), by filtering artifacts.

The MII/pH monitoring is performed through a neonatal catheter (Infant Comfort TEC®) with 7 impedence electrodes (creating 6 impedance channels) and one pH detector able to cover the whole distance from the pharynx to the lower esophageal sphincter (LES) (channel 1). The pH detector is placed within channel 1, 1.5 cm above the LES. The correct positioning of the catheter is measured through fluoroscopy and eventually corrected. Data obtained from impedance channels that result proximal to the superior esophageal sphincter are excluded from the analysis. The acquisition and recording of MII/pH data are performed through Sleuth System, Sandhill Scientific Inc., Highlands Ranch, Colorado, USA. The analysis of MII/pH tracings is made visually by a single operator using BioView 5.3.4 software (Sleuth System, Sandhill Scientific Inc., Highlands Ranch, Colorado, USA).

The variables analyzed are listed as follows:

Clinical variables:

  • feeding time (min)
  • feeding total volume (mL)
  • n. GER during feeding
  • n. GER in the post-prandial period (150 min after feeding)

Cardiorespiratory variables:

  • frequency of apnea, desaturation and bradycardia during feeding
  • frequency of apnea, desaturation and bradycardia during post-prandial period
  • mean duration of apnea during feeding and post-prandial period
  • mean and minimum desaturation level during feeding and post-prandial period
  • mean and minimum heart rate during feeding and post-prandial period

MII/pH variables:

  • Swallow frequency during feeding and post-prandial period (events/h)
  • Bolus Presence Time (BPT): seconds between bolus entry and bolus exit in the distal channel
  • Bolus Head Advancing Time (BHAT): seconds between bolus entry in proximal channel and entry in distal channel
  • Bolus Head Advancing Time Corrected for Esophageal Length (BHATc): BHAT corrected for esophageal length (BHATc = BHAT / esophageal length)
  • Reflux pH: minimum pH value registered during each GER event. It classifies refluxes into 3 different types: acid (pH < 4), weakly acid (pH 4-7) and weakly alkaline (pH > 7)
  • GER frequency, (events/h)
  • Bolus Clearance Time (BCT): reflux duration, recorded at distal channel (s)
  • Bolus Reflux Extent (BRE), (n. channels)
  • Proximal GER frequency (events/h)
  • Bolus Exposure Index (BEI): percentage of time in which GER involves esophagus during MII/pH monitoring
  • Reflux Index (RI): percentage of time during which pH falls below 4 during MII/pH monitoring

Randomization: the alternate use of feeding bottles A and B is set by a binary random sequencing generated by Microsoft Office Excel software that indicates the first feeding bottle to be used. This is a single-blind study since the sequence is unknown to the specialist in charge of reporting MII/pH and CR monitoring.

Statistical analysis:

The analysis is made with Statistical Software Package For Windows® (StatSoft, Inc., Tulsa, Oklahoma, USA). Kolmogorov-Smirnov test and exploratory data analysis are used to define normality range. Data will be expressed as mean and standard deviation (SD), or as median and interquartile range if more appropriate. Differences among cardiorespiratory and MII/pH variables will be evaluated with Student paired T test or Wilcoxon test if more appropriate. Significance will be considered as p<0.05.

Conditions
GERD, Apnea Neonatal
Being tested
A, B
Keywords
gastroesophageal reflux, swallow, feeding bottle, cardiorespiratory, apnoea, preterm, impedance-pH-metry
Medical subject headings
Gastroesophageal Reflux, Bottle Feeding, Apnea, Premature Birth

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ADevice

    standard bottle

  • BDevice

    vented base bottle

Study groups in NCT03031288
Study groupRoleWhat they receive
Start feeding with Device A, "standard"ExperimentalAlternatively feeding with standard feeding bottle (Device A) and vented base feeding bottle (Device B)
Receives: Device: A; Device: B
Start feeding with Device B, "vented"ExperimentalAlternatively feeding with vented base feeding bottle (Device B) and standard feeding bottle (Device A)
Receives: Device: A; Device: B

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Frequency of cardiorespiratory events (feeding+postprandial time)

    Cardiorespiratory events / hour

    • apnea (no breathing movement for at least 20 s, or less if associated with desaturation/bradycardia)
    • desaturation (SpO2 <80%)
    • bradycardia (heart rate < 80 bpm for at least 1 s)

    Measured: calculated throughout 24 hour

Secondary outcomes (2)
  1. Swallow event characteristics (feeding time)

    Swallow event is identified as a rapid increase in impedance preceded by a drop in impedance to 50% of baseline beginning in the proximal channel and proceeding in an anterograde direction to the most distal channel, followed by the recovery of baseline values at each channel

    Measured: calculated throughout 30 minute interval after the beginning of the milk meal

  2. Frequency of reflux events (postprandial time)

    Reflux event is defined as: a drop of impedance to 50% of the basal value for at least 5 s, starting in the most distal channel and proceeding to one or more proximal channels and followed by a recovery of the impedance baseline values

    Measured: calculated throughout 150 minute interval after the end of the milk meal

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jan 2017 (estimated)
  2. Study start1 Jan 2017
  3. Primary completion1 Dec 2018
  4. Study completion1 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Investigator
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03031288
Sponsor's protocol ID
feeding-01
Acronym
FeedGERD
Status last verified
Mar 2020
First submitted
12 Jan 2017
Last updated
31 Mar 2020
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing A and B in people with GERD and Apnea Neonatal, run by University of Turin, Italy at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Frequency of cardiorespiratory events (feeding+postprandial time) (time frame: calculated throughout 24 hour). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in